CRNX — Crinetics Pharmaceuticals Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $38.9
- 30-Day Move
- -21.1%
- Market Cap
- $3.9B
- Shares Outstanding
- 104,710,000
- P/B Ratio
- 4.45
- ROE
- -46.9%
Analyst consensus: Buy · 22 analysts
Crinetics Pharmaceuticals Inc
A read-only Alphactor snapshot forCrinetics Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$38.9
30-Day Move
-21.1%
Market Cap
$3.9B
Shares Outstanding
104,710,000
P/B Ratio
4.45
ROE
-46.9%
$38.90
-21.1%last 90 delayed daily bars
90D High
$57.99
90D Low
$33.10
Avg Volume
1,183,276
Gross margin is running at 86.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -6046.2%, useful for comparing CRNX against peers in Pharmaceuticals.
CRNX is down 21.1% over the last 30 trading days shown on this page.
Latest operating income is $-134M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$0.87
Rule of 40
-4344.8%
Latest Close
$38.9
30-Day Move
-21.1%
Market Cap
$3.9B
Shares Outstanding
104,710,000
P/B Ratio
4.45
ROE
-46.9%
ROA
-41.3%
Gross Margin
86.0%
Operating Margin
-6714.8%
Net Margin
-6046.2%
Debt / Equity
0
Current Ratio
12.32
Latest Revenue
$6M
Revenue
$6M
Gross Profit
--
Operating Income
$-134M
Net Income
$-123M
Gross Margin
8602.0%
Net Margin
-604622.0%
Current Ratio
12.32
Debt / Equity
0.00
Fair Value
$0.87
Upside / Downside
-97.8%
Signal
Overvalued
Implied Growth
--
EV/Rev
$0.87
Growth Assumption
17.6%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
15.19
Safe
Piotroski
2
Weak (0-3)
Cash Conversion
0.81x
Rule of 40
-4344.8%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $5M | $-168M | $-164M | $-117M |
| 2023-12-31 | $4M | $-223M | $-215M | $-173M |
| 2024-12-31 | $1M | $-339M | $-298M | $-234M |
| 2025-12-31 | $8M | $-517M | $-465M | $-384M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$12M
Buys
0
Sells
22
Buy Value
$0
Sell Value
$12M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-08 | Knight Jeff E. | M | 19,336 | $0.00 |
| 2026-04-08 | Knight Jeff E. | M | 9,624 | $0.00 |
| 2026-04-08 | Knight Jeff E. | M | 49,474 | $0.00 |
| 2026-04-08 | Knight Jeff E. | Sell | 85,163 | $40.10 |
| 2026-04-08 | Knight Jeff E. | M | 19,336 | $19.64 |
| 2026-04-08 | Knight Jeff E. | M | 9,624 | $20.02 |
| 2026-04-08 | Knight Jeff E. | M | 49,474 | $23.98 |
| 2026-03-16 | Knight Jeff E. | Sell | 3,961 | $37.77 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3,494,255 | 0.03% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,970,777 | 0.03% | 2025-12-31 |
| Fidelity Securities Fund-Fidelity OTC Portfolio | 2,734,323 | 0.03% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 2,372,451 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2,152,815 | 0.02% | 2025-12-31 |
| T. Rowe Price New Horizons Fund, Inc. | 1,492,204 | 0.01% | 2025-12-31 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1,280,000 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1,217,056 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2025-11-14
--
--
Two Sigma Advisers
Filed 2026-02-17
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$665M
+0.7%
Vanguard Group
Filed 2026-01-29
$425M
-0.4%
Farallon Capital
Filed 2026-02-17
$323M
+20.2%
BlackRock
Filed 2024-08-13
$279M
--
Geode Capital Management
Filed 2026-02-09
$104M
-1.6%
4.23
Consensus
Buy—
—
—
22
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.